SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment

Abstract Background The combination of oncolytic viruses (OVs) with immune checkpoint blockades is a research hotspot and has shown good efficacy. Here, we present the first attempt to combine oncolytic herpes simplex virus 2 (OH2) with an anti-SIRPα antibody as an antitumour treatment. Our results...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Defeng Kong, Zhenrong Yang, Guoliang Li, Quanyou Wu, Zhaoru Gu, Duo Wan, Qi Zhang, Xiaoli Zhang, Shujun Cheng, Binlei Liu, Kaitai Zhang, Wen Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-10-01
Colecção:	BMC Medicine
Assuntos:	Oncolytic virus Oncolytic herpes simplex virus 2 SIRPα Macrophage Tumour microenvironment environment
Acesso em linha:	https://doi.org/10.1186/s12916-022-02574-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!